Urolithin A with Resveratrol

Reviewed by SOMA HEALTH's Medical Research Team

Urolithin A and resveratrol often appear on the same shortlist of longevity-minded ingredients, and plenty of people are curious about running both in one routine. They are not the same kind of compound, though, and their human evidence is at very different stages. This guide walks through what each one is, what the research genuinely supports, and how to think about combining them honestly.

Two longevity ingredients, side by side

Both urolithin A and resveratrol are plant-derived polyphenol compounds that have drawn attention for their possible roles in healthy aging. That is roughly where the similarity ends. They act through different biology, they have been studied for different endpoints, and the maturity of their human evidence differs. Putting them next to each other is useful precisely because it clarifies what each one can and cannot claim.

What resveratrol is

Resveratrol is a polyphenol found in grapes, red wine, peanuts and some berries. It became famous through research into sirtuins, a family of proteins, and particularly SIRT1, which is involved in cellular stress responses and metabolism. Early laboratory and animal work suggested resveratrol could activate SIRT1 and mimic aspects of caloric restriction, which is what fueled the longevity excitement.

The human picture is more cautious. A well-known challenge with resveratrol is bioavailability: it is absorbed and then metabolized quickly, so relatively little circulates in an active form. Human trials have been mixed, and whether resveratrol meaningfully activates SIRT1 at practical oral doses in people remains debated. As a structure/function ingredient it is described in terms of antioxidant support; it is not a treatment for any disease, and the longevity claims that surround it run well ahead of what human data have settled. That gap between enthusiasm and evidence is the single most important thing to understand about resveratrol.

What urolithin A is, and what the human evidence shows

Urolithin A is a gut postbiotic. Your microbiome produces it from ellagitannins, compounds in pomegranate, walnuts and berries, and only some people carry the bacteria to convert it efficiently, which is a major reason a standardized supplement is useful. Its most-studied mechanism is support for mitophagy, the process by which cells identify worn-out mitochondria and recycle them so healthier ones can take over. In other words, resveratrol's story is built around a signaling protein, while urolithin A's story is built around a concrete quality-control process for your cellular power plants.

Proven in humans

Urolithin A's human evidence is comparatively developed, and it is worth stating precisely. The first-in-human trial (Andreux and colleagues, Nature Metabolism, 2019) found it safe and well tolerated at doses up to 1,000 mg per day and reported a mitochondrial gene-expression signature in muscle. A randomized trial in middle-aged adults (Singh and colleagues, Cell Reports Medicine, 2022) tested 500 mg and 1,000 mg arms over four months and reported gains in muscle strength and exercise performance. A randomized study in older adults (Liu and D'Amico and colleagues, JAMA Network Open, 2022) reported improved muscle endurance over about four months. An eight-week randomized trial in resistance-trained men (Journal of the International Society of Sports Nutrition, 2024) adds further human data on the exercise front.

Newer human research

Recent work has moved beyond muscle. A 2025 randomized trial (Nature Aging) of roughly 28 days reported that urolithin A supported the mitochondrial health of immune cells in midlife adults, a topic tied to inflammaging. A 2025 trial in distance runners has also been published. Balancing this, a 2024 systematic review in Ageing Research Reviews on targeting aging with urolithin A in humans concluded the evidence is still emerging, which is the fair way to summarize the whole field.

Preclinical background

The mechanistic groundwork is largely preclinical and should be labeled as such. The foundational study (Ryu and colleagues, Nature Medicine, 2016) showed urolithin A triggered mitophagy and extended lifespan in the worm C. elegans and improved muscle measures in rodents. Preclinical models have also examined joint and cartilage endpoints (D'Amico and colleagues, Aging Cell, 2022). Applications to skin, gut, brain and heart remain early, preclinical exploration rather than proven human outcomes.

Why people combine them, and the honest limits

The appeal of running both is that they target different aspects of aging biology: resveratrol is associated with sirtuin signaling, while urolithin A supports mitophagy. On paper they do not overlap, which is why they land in the same routine for people who take a broad approach. The honest caveat is important, though. There is no large human trial that tested this specific combination and measured a shared benefit. Urolithin A's human case rests on urolithin A trials; resveratrol's human evidence is genuinely mixed and its longevity claims are largely unsettled in people. Pairing them is a personal, evidence-aware choice, not a proven strategy, and it is worth resisting the marketing instinct to treat two ingredients as automatically better than one.

How to combine them sensibly

If you choose to use both, keep it simple. Urolithin A has been studied at 500 to 1,000 mg per day; our urolithin A dosage guide covers the range in detail. Both are polyphenol-type compounds and are commonly taken with food. Give any routine a fair, consistent trial rather than judging it day to day, since these are maintenance ingredients rather than acute stimulants. For the bigger context, our urolithin A guide and our roundup of the best urolithin A gummies lay out how urolithin A fits into a daily plan, and our overview of the urolithin A benefits supported by research is a useful companion. Because resveratrol interacts with some medications and its data are mixed, this is not a treatment recommendation; anyone with a medical condition, on prescription medicine, or who is pregnant or nursing should check with their doctor before combining supplements.

The bottom line

Urolithin A and resveratrol both belong to the longevity conversation, but they are at different levels of evidence. Urolithin A has a growing base of human randomized trials, most established for muscle strength and endurance and now extending into immune-cell mitochondrial health, with much of its broader promise still preclinical. Resveratrol has an interesting mechanistic backstory and real questions about how much reaches an active form in people. Using them together can be reasonable, but the case for each should be judged on its own evidence rather than on a hoped-for synergy.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.